PV Bulletin

EMA/HMA Workshop Recommendations on Mechanistic Model Reporting and Qualification

HMA/EMA workshop report recommends establishing a standing forum for strategic MIDD dialogue, enhancing product-specific interaction pathways, and updating guidance on qualification and reporting of mechanistic models (e.g., QSP/QST) for regulatory assessment.

Primary source: European Medicines Agency (EMA)

PV Impact Brief

Urgency: LowConfidence: high

What changed

EMA and HMA issued final workshop recommendations establishing a standing forum for strategic MIDD Agency-developer dialogue, enhancing product-specific MIDD pathways, and updating guidance to delineate platform qualification and reporting requirements for mechanistic models.

Why it matters

Mechanistic models are increasingly used in safety assessment and signal management; these recommendations will directly affect how sponsors prepare and present mechanistic safety evidence in dossiers and safety reviews within the EU.

Action needed

Review updated EMA guidance on mechanistic model reporting and qualification when published; align sponsor submissions with new qualification pathways and reporting requirements for MIDD and safety-related models.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

monitor

Policy change details

Document type
Report
Policy status
final
Publication date
2026-06-05
Policy change
This report summarizes the findings of a workshop focused on the reporting and qualification of mechanistic models (e.g., QSP/QST) within the EU regulatory framework. It outlines recommendations for strategic dialogue and guidance refinement to streamline the use of these models in regulatory assessment.

Key changes

Key recommendations include establishing a standing forum for strategic MIDD Agency-developer dialogue, enhancing product-specific interaction pathways for MIDD, and updating guidance to delineate platform qualification and reporting requirements.

Affected workflows

Signal Management

Responsible groups

Pharmacovigilance OperationsRegulatory AffairsSafety/Pharmacology Teams

PV impact

Mechanistic models are increasingly used in safety assessment and signal management. The recommendations for clearer qualification pathways and reporting requirements will impact how sponsors present mechanistic safety evidence in dossiers and safety reviews.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 5, 2026

Full briefing

Practical implication

Review updated EMA guidance on mechanistic model reporting and qualification when published; align sponsor submissions with new qualification pathways and reporting requirements for MIDD and safety-related models.

The report outlines recommendations to streamline the use of mechanistic models in EU regulatory assessment, including clearer qualification pathways and reporting requirements, impacting how sponsors present mechanistic safety evidence.

What changed: EMA and HMA issued final workshop recommendations establishing a standing forum for strategic MIDD Agency-developer dialogue, enhancing product-specific MIDD pathways, and updating guidance to delineate platform qualification and reporting requirements for mechanistic models.

Why it matters: Mechanistic models are increasingly used in safety assessment and signal management; these recommendations will directly affect how sponsors prepare and present mechanistic safety evidence in dossiers and safety reviews within the EU.

Practical implication: Review updated EMA guidance on mechanistic model reporting and qualification when published; align sponsor submissions with new qualification pathways and reporting requirements for MIDD and safety-related models.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward